Clinical trials: Open Angle Glaucoma -Ocular Hypertension
Ocular Hypertension, Glaucoma
A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients
The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.
- Conditions
- Ocular Hypertension, Glaucoma, Open-angle Glaucoma
- Trial name
- NCT00856622
- Testing
- i. Fixed combination of latanoprost 0.005% and timolol 0.5%, timolol 0.5% ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 37 sites in Germany
- Volunteers
- 436 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open Angle, Ocular Hypertension
A 12week, Randomized, Evaluator-Masked, Parallel Group Comparing Evening Dosing Of Xalacom Vs Cosopt In Subj W/ Glaucoma
To demonstrate the statistical non inferiority of the combination of latanoprost and timolol given in the evening time once a day vs the combination of dorzamalide and timolol twice a day based on intraocular pressure…
- Trial name
- NCT00140049
- Testing
- Xalacom, Cosopt
- Where
- 25 sites in France, Germany and 3 more
- Volunteers
- 238 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open Angle, Ocular Hypertension
Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension
to compare efficacy and safety of Xalacom with the combination of unfixed Latanoprost and Timolol in subjects with open-angel glaucoma or ocular hypertension
- Trial name
- NCT00219596
- Testing
- Xalacom, unfixed Latanoprost and Timolol
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12.
- Trial name
- NCT00277498
- Testing
- Xalacom, Xalatan, Timolol
- Where
- 64 sites in United States
- Volunteers
- 528 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Corneal Versus Conjunctival Delivery Using a Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
- Trial name
- NCT00143429
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery Device
Compare the antihypertensive efficacy of two methods for instilling Xalatan eyedrops
- Trial name
- NCT00283764
- Testing
- Xalatan
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada
This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed ocular hypertension and open-angle glaucoma patients in Canada.
- Trial name
- NCT00334750
- Testing
- There is no intervention in this study.
- Where
- 21 sites in Canada
- Volunteers
- 410 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Open-Angle, Ocular Hypertension
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00647101
- Testing
- Latanoprost
- Where
- 176 sites in France
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Open Angle Glaucoma
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
Study PhXA41 for its non-inferiority compared with timolol in lowering intra-ocular pressure
- Trial name
- NCT00751049
- Testing
- timolol, PhXA41
- Where
- 12 sites in United Kingdom
- Volunteers
- 294 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia
PhXA41 is not inferior to timolol in reducing intra-ocular pressure
- Trial name
- NCT00751062
- Testing
- timolol, PhXA41
- Where
- 13 sites in Denmark, Finland and 2 more
- Volunteers
- 267 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
The primary objective of this study was to compare the change in intraocular pressure (IOP) of three different doses of latanoprost (75, 100 and 125 ug/ml) to that of the marketed 50 ug/ml dose, in a dose ranging study.
- Trial name
- NCT01379144
- Testing
- latanoprost 75 ug, latanoprost 100 ug, latanoprost 125 ug
- Where
- 25 sites in Australia, Czechia and 6 more
- Volunteers
- 282 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Open Angle Glaucoma, Ocular Hypertension
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared to Timolol maleate 0.5% after 28…
- Trial name
- SYLTAG (NCT02250612)
- Testing
- 1 drop of 0.375% SYL040012 (bamosiran), 1 drop of 0.750% SYL040012 (bamosiran), 1 drop of 1.125% SYL040012 (bamosiran)
- Where
- 21 sites in United States, Estonia and 2 more
- Volunteers
- 184 people
- Sponsor
- Sylentis, S.A.
Glaucoma, Ocular Hypertension
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
This purpose of this study is to access the efficacy, tolerability and safety of RKI983 (0.05% and 0.10%) ophthalmic solution bid versus once daily latanoprost 0.005%, in patients with POAG or ocular hypertension.
- Trial name
- NCT00846989
- Testing
- RKI983A, Latanoprost
- Where
- 29 sites in United States
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Primary Open-angle Glaucoma, Ocular Hypertension
Adherence With Fixed Versus Unfixed Glaucoma Therapy
A 6-month, parallel, non-interventional trial investigating the level of adherence and the impact of dosing in open-angle glaucoma patients who receive either unfixed therapy with latanoprost once in the evening and timolol twice…
- Conditions
- Primary Open-angle Glaucoma, Ocular Hypertension, Exfoliation Glaucoma
- Trial name
- NCT01281020
- Where
- Greece
- Volunteers
- 132 people
- Sponsor
- Aristotle University Of Thessaloniki
Glaucoma, Primary Open Angle Glaucoma
Tafluprost Preservative Free Switch Study
This study is conducted to document the effect of switching from preserved prostaglandin analogues monotherapy to preservative free tafluprost 0.0015%. The endpoints analyzed are side effect improvement in these patients.
- Conditions
- Glaucoma, Primary Open Angle Glaucoma, Ocular Hypertension
- Trial name
- NCT04654611
- Testing
- preservative free tafluprost 0.0015%
- Where
- Malaysia
- Volunteers
- 28 people
- Sponsor
- Tun Hussein Onn National Eye Hospital
Glaucoma, Primary Open Angle, Ocular Hypertension
Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to compare the efficacy and tolerance of generic travoprost with its brand name formulation. In this open label, randomized, crossover study, the primary outcome will be intraocular pressure and the…
- Trial name
- NCT02796560
- Testing
- Brand name travoprost, Generic travoprost
- Where
- Canada
- Volunteers
- 76 people
- Sponsor
- Université de Sherbrooke
Open Angle Glaucoma, Ocular Hypertension
180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma
Selective laser trabeculoplasty (SLT) is a well-recognized way to lower eye pressure in treatment of glaucoma. This treatment is performed for 180 degrees or 360 degrees, and studies at academic centers have shown mixed results…
- Conditions
- Open Angle Glaucoma, Ocular Hypertension, Glaucoma, Open Angle, Pseudo-exfoliative, Pigment Dispersion Syndrome
- Trial name
- NCT02628223
- Testing
- Selective Laser Trabeculoplasty, Neodymium:Yttrium Aluminum Garnet (YAG) laser
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- Temple University
Primary Open-angle Glaucoma, Primary Angle-Closure Glaucoma
Prevalence of Ocular Surface Disease in Malaysian Glaucoma Patients
This is a prospective, multi-centre, cross sectional observational study to determine the prevalence of ocular surface disease (OSD) in glaucoma patients, nationwide.
- Conditions
- Primary Open-angle Glaucoma, Primary Angle-Closure Glaucoma, Pseudoexfoliation Glaucoma, Pigment Dispersion Glaucoma
- Trial name
- NCT04609345
- Volunteers
- 400 people
- Sponsor
- Santen Pharma Malaysia Sdn Bhd
Open-angle Glaucoma, Ocular Hypertension
A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study
Treatment of elevated pressure in the eye (Intraocular pressure, or 'IOP') with eye drop medications has been shown to be effective in delaying or preventing the progression of glaucoma, and it is the only proven method for…
- Trial name
- NCT03216902
- Testing
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution
- Where
- 17 sites in United States, Japan
- Volunteers
- 241 people
- Sponsor
- Santen Inc.